佛罗里达州慢性咳患者处方咳药物的模式:2012-2021年
Seonkyeong Yang1, Shu Huang1, Juan M Hincapie-Castillo2
1Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida, Gainesville, FL 32611, USA.
Journal of clinical medicine
|October 14, 2023
概括
慢性咳 (CC) 药物处方的趋势显示,使用松酸盐,德克斯特罗米多芬和 gabapentinoids 的比例增加,而阿片类抗咳药的使用率下降. 很少有CC患者长期使用药物,这表明疾病负担很大.
科学领域:
- 肺病学和药理学 肺病学和药理学
- 医疗保健中的现实世界证据
背景情况:
- 慢性咳 (CC) 对健康造成重大负担,通常需要长期管理.
- 了解药物处方模式对于优化CC治疗策略至关重要.
研究的目的:
- 分析慢性咳患者处方咳药物 (CM) 的趋势.
- 在现实世界的队列中识别不同的CM利用轨迹.
主要方法:
- 使用OneFlorida临床研究联盟数据库 (2012-2021) 进行的回顾性队列研究.
- 进行重复的横截面分析以确定趋势,并对利用模式进行基于组的轨迹建模 (GBTM).
- 分析包括15566名CC患者和655250名非CC患者,不包括患有癌症的患者.
主要成果:
- 从2012年到2021年,佐酸盐,德克斯特罗梅索芬和 gabapentinoid 的使用在 CC 患者中显著增加.
- 在下降之前,阿片类抗咳药的使用在2015年达到峰值;整体的CM使用仍然有限.
- GBTM确定了三个轨迹:没有使用CM (72.1%),使用量下降 (26.4%),和慢性使用 (1.5%).
- 与非CC患者相比,CC患者表现出更高的并发病率和医疗服务利用率.
结论:
- 佛罗里达州的慢性咳患者显示,随着非阿片类药物的使用越来越多,CM处方模式正在演变.
- 一小部分但显著的CC患者需要慢性CM,突出显著的疾病负担.
- 对有效和可持续的CC管理进行进一步研究是有必要的.
相关概念视频
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
304
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by...
304
Drugs Used in Lower Respiratory Disorders: Overview
462
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
462
Inhaled Medications
292
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
292
Drugs Used in Upper Respiratory Disorders: Overview
265
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
265
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Chronic Obstructive Pulmonary Disease
1.3K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.3K


